Evaluation of manganese-trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging
Preclinical evaluation of a 0.5 M solution of the manganese(II)- trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 = 3.68 (mM(-1) x s(-1)) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Eksperimental'naia i klinicheskaia farmakologiia - 76(2013), 10 vom: 08., Seite 32-8 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Usov, V Iu [VerfasserIn] |
|---|
| Themen: |
482-54-2 |
|---|
| Anmerkungen: |
Date Completed 11.03.2014 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM234255706 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM234255706 | ||
| 003 | DE-627 | ||
| 005 | 20231224100857.0 | ||
| 007 | tu | ||
| 008 | 231224s2013 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n0780.xml |
| 035 | |a (DE-627)NLM234255706 | ||
| 035 | |a (NLM)24400387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Usov, V Iu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of manganese-trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2014 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Preclinical evaluation of a 0.5 M solution of the manganese(II)- trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 = 3.68 (mM(-1) x s(-1)) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Contrast Media |2 NLM | |
| 650 | 7 | |a CDTA |2 NLM | |
| 650 | 7 | |a 482-54-2 |2 NLM | |
| 650 | 7 | |a Edetic Acid |2 NLM | |
| 650 | 7 | |a 9G34HU7RV0 |2 NLM | |
| 700 | 1 | |a Balianin, M L |e verfasserin |4 aut | |
| 700 | 1 | |a Bezlepkin, A I |e verfasserin |4 aut | |
| 700 | 1 | |a Churin, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Dubskaia, T Iu |e verfasserin |4 aut | |
| 700 | 1 | |a Vetoshkina, T L |e verfasserin |4 aut | |
| 700 | 1 | |a Filimonov, V D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Eksperimental'naia i klinicheskaia farmakologiia |d 1997 |g 76(2013), 10 vom: 08., Seite 32-8 |w (DE-627)NLM012612790 |x 0869-2092 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2013 |g number:10 |g day:08 |g pages:32-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2013 |e 10 |b 08 |h 32-8 | ||